FACP; report prepared by Jane de Lartigue

Article

Expanded approval for daratumumab in multiple myeloma

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Ribociclib: another CDK inhibitor hits the mark in breast cancer

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Approval makes olaratumab the first first-line treatment option for soft tissue sarcoma in more than 40 years

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Rucaparib – second PARP inhibitor hits the market for ovarian cancer

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Fourth approved indication for ofatumumab in chronic lymphocytic leukemia

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Renal cell carcinoma approval adds another notch to cabozantinib’s belt

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More

Article

Panobinostat: a novel mechanism of action shows promise in multiple myeloma

Author:: Edited by Jame Abraham; MD; FACP; report prepared by Jane de Lartigue; PhD

Read More